Share Buyback in H. Lundbeck A/S


During any one single trading day a maximum of 25% of the average
daily trading volume of Lundbeck shares on the Copenhagen Stock
Exchange, calculated over 20 days prior to each trading date, will be
bought back, as the share buyback program is implemented in
accordance with the provisions of the European Commission's
regulation no. 2273/2003 of December 22, 2003.

At least once every seven trading days, Lundbeck will issue an
announcement in respect of the transactions made under the program.

The following transactions have been made under the program:


                       No. of shares        Average Transaction value
                                     purchase price             (DKK)
                                              (DKK)
Accumulated, last         25,168,102       135.7029     3,415,384,166
announcement
10 December 2007              36,888       147.0857 5,425,696.08
11 December 2007                  --             -- --
12 December 2007              14,514       149.3588 2,167,793.68
13 December 2007             112,915       147.2168     16,622,986.01
14 December 2007                  --             -- --
17 December 2007             118,801       148.9786     17,698,805.72
18 December 2007             119,059       145.9405     17,375,533.60
Accumulated under the     25,570,279       135.8873     3,474,674,981
program



Following the above buyback it is hereby announced that Lundbeck owns
a total of 5,867,644 own shares at a nominal value of DKK 5, equal to
3.09% of the total number of 207,279,631 shares.

The content of this release will have no influence on the Lundbeck
Group's financial result for 2007.

Lundbeck contacts


Investors:                    Media:

Jacob Tolstrup                Anders Schroll
Director, Corporate Reporting Head of Communication
+45 36 43 30 79               +45 36 43 20 81

Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26


                      ________________________

Stock Exchange Release No 315 - 18 December 2007

About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com

Attachments

Release No 315 in pdf format